Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
- Gary E. Meininger, MD1,
- Russell Scott, MD2,
- Maria Alba, MD1,
- Yue Shentu, PHD1,
- Edmund Luo, PHD1,
- Himal Amin, BS1,
- Michael J. Davies, PHD1,
- Keith D. Kaufman, MD1 and
- Barry J. Goldstein, MD, PHD1⇓
- 1Merck Sharp & Dohme Corp., Rahway, New Jersey
- 2Lipids and Diabetes Research Group, Christchurch School of Medicine, Christchurch, New Zealand
- Corresponding author: Barry J. Goldstein, .
OBJECTIVE To assess the efficacy and safety of MK-0941, a glucokinase activator (GKA), when added to stable-dose insulin glargine in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS In this double-blind study, 587 patients taking stable-dose insulin glargine (±metformin ≥1,500 mg/day) were randomized (1:1:1:1:1) to MK-0941 10, 20, 30, or 40 mg or matching placebo t.i.d. before meals (a.c.). This study included an initial 14-week, dose-ranging phase followed by a 40-week treatment phase during which patients were to be uptitrated as tolerated to 40 mg (or placebo) t.i.d. a.c. The primary efficacy end point was change from baseline in A1C at Week 14.
RESULTS At Week 14, A1C and 2-h postmeal glucose (PMG) improved significantly versus placebo with all MK-0941 doses. Maximal placebo-adjusted least squares mean changes from baseline in A1C (baseline A1C 9.0%) and 2-h PMG were −0.8% and −37 mg/dL (−2 mmol/L), respectively. No significant effects on fasting plasma glucose were observed at any dose versus placebo. By 30 weeks, the initial glycemic responses noted at 14 weeks were not sustained. MK-0941 at one or more doses was associated with significant increases in the incidence of hypoglycemia, triglycerides, systolic blood pressure, and proportion of patients meeting criteria for predefined limits of change for increased diastolic blood pressure.
CONCLUSIONS In patients receiving stable-dose insulin glargine, the GKA MK-0941 led to improvements in glycemic control that were not sustained. MK-0941 was associated with an increased incidence of hypoglycemia and elevations in triglycerides and blood pressure.
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1200/-/DC1.
G.E.M. and M.A. are currently affiliated with Johnson & Johnson Pharmaceutical Research & Development, Raritan, New Jersey. E.L. is currently affiliated with Forest Laboratories, Jersey City, New Jersey.
A complete list of MK-0941 Study 007 investigators can be found in the Supplementary Data online.
- Received June 23, 2011.
- Accepted September 2, 2011.
- © 2011 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.